Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 3, 2007
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the JP Morgan Health Care Conference, which is being held January 8 - 11 in...
-
Jan 2, 2007Trial highlights the importance of appropriate pacing for patients at risk of sudden cardiac death
Boston Scientific Corporation (NYSE: BSX) today announced that results of the largest implantable cardioverter defibrillator (ICD) study to date,...
-
Dec 15, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling certain lots of the Mach 1® Guide Catheter in the...
-
Dec 14, 2006Device now cleared for use in both carotid arteries and saphenous vein grafts
Boston Scientific Corporation (NYSE: BSX) today announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market its...
-
Dec 7, 2006
Boston Scientific Corporation (NYSE: BSX) today presented data on its 7,000- patient ARRIVE I and II registries of real-world...
-
Dec 7, 2006
Boston Scientific Corporation (NYSE: BSX) today presented data on its long- term randomized clinical trials to a special U.S....
-
Nov 21, 2006
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held November 29...
-
Nov 15, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Brenda Becker will be appointed Senior Vice President of Global Government Affairs....
-
Nov 14, 2006Lower re-intervention rates for the TAXUS Stent in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed a presentation by Joost Daemen, M.D., and Patrick Serruys, M.D., entitled...
-
Nov 9, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's LATITUDE® 2.0...
-
Nov 6, 2006
At a meeting with analysts today, Boston Scientific Corporation (NYSE: BSX) provided its financial outlook for 2007. Sales goals for 2007 range...
-
Nov 6, 2006
Boston Scientific Corporation (NYSE: BSX) today presented a four-year update of its key randomized, controlled clinical trials (TAXUS II, IV, V and...
-
Nov 6, 2006Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Nov 3, 2006Company to acquire EndoTex
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the NexStent® Carotid Stent...
-
Nov 3, 2006Innovative Technology Makes Precision™ Spinal Cord Stimulator Accessible to More Patients
Boston Scientific Corporation (NYSE: BSX) today announced that it has received the European CE Mark for its new Artisan™ 2x8 Surgical Lead for use...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Daniel J. Brennan has been appointed to the position of Vice President Investor...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) will simultaneously webcast the analyst meeting it is hosting on Monday, November 6. The meeting is...
-
Nov 1, 2006Thousands of Heart Failure Patients Are Now Eligible for Additional Pacing Feature
Boston Scientific Corporation (NYSE: BSX) today announced the launch of software enabling its Left Ventricular (LV) Offset feature in the Company's...
-
Oct 31, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Steven L. Zelenkofske, D.O., F.A.C.C., has been appointed Patient Safety Officer and...
-
Oct 25, 2006Positive results also reported for TAXUS Liberte stent direct stenting
Boston Scientific Corporation (NYSE: BSX) today announced 12-month follow-up data from TAXUS ATLAS, the pivotal clinical trial...
-
Oct 25, 2006
Boston Scientific Corporation (NYSE: BSX) today announced positive results from its global TAXUS OLYMPIA registry, supporting the...
-
Oct 23, 2006Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent
Boston Scientific Corporation (NYSE: BSX) today announced that an independent meta-analysis of more than 3,500 patients from five...
-
Oct 23, 2006Two-year results continue to evaluate long-term safety and efficacy
Boston Scientific (NYSE: BSX) today announced two-year data from its BEACH carotid artery stenting (CAS) clinical trial. The study...
-
Oct 23, 2006Multi-center registry to enroll 10,000 patients over two years
Boston Scientific Corporation (NYSE: BSX) today announced that it intends to provide lead financial support for an extension of the...
-
Oct 22, 2006
Boston Scientific Corporation (NYSE: BSX) today announced one-year results from its TC-WYRE (TAXUS® Express2™ Stent vs. Cypher Stent: What's...
-
Oct 18, 2006
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2006. Net sales for the third...
-
Oct 18, 2006Results to include new data on next-generation TAXUS® Liberte™ Stent System
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular...
-
Oct 16, 2006
Boston Scientific Corporation (NYSE: BSX) today announced the initiation of a new clinical trial designed to identify and investigate clinically...
-
Oct 16, 2006PROMUS stent to complement Company's market-leading TAXUS® stent systems
Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...
-
Oct 12, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the validity of a key...
-
Oct 4, 2006
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Oct 2, 2006FDA approval makes remote monitoring available by more than 150,000 additional patients
Boston Scientific Corporation (NYSE: BSX) today announced a U.S. Food and Drug Administration (FDA) approval that permits the LATITUDE® Patient...
-
Sep 29, 2006Gobierno de Puerto Rico aprueba el Sistema Precision, que brinda a los médicos una nueva opción de tratamiento para dolor agudo y crónico
Boston Scientific Corporation (NYSE: BSX) anunció hoy sobre el primer paciente implantado en Puerto Rico con el Precision Spinal Cord Stimulation...
-
Sep 28, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that it plans to adopt the recommendations announced today by the Heart Rhythm Society...
-
Sep 27, 2006
Boston Scientific Corporation (NYSE: BSX) today announced the approval of its new Harmony™ HiResolution® Bionic Ear System (Harmony System) by...
-
Sep 26, 2006CryoPlasty® Therapy may be an alternative to surgery or limb amputation
Boston Scientific Corporation (NYSE: BSX) today announced excellent six-month results from its Below-The-Knee (BTK) CHILL trial. This study, a...
-
Sep 21, 2006
Boston Scientific Corporation (NYSE: BSX) today announced preliminary net sales and earnings for its third quarter ending September 30, 2006....
-
Sep 19, 2006FLEXView™ System enables physicians to perform less-invasive cardiac surgical ablation procedures
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. market launch of the FLEXView™ System for unilateral visualization and...
-
Sep 14, 2006
Boston Scientific Corporation (NYSE: BSX) today issued the following comment on the statement of the U.S. Food and Drug Administration on...
-
Sep 13, 2006
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of two studies and an editorial published in today's edition of The New...
-
Sep 6, 2006Overall cardiac death rate for combined bare-metal control group equivalent to TAXUS slow- and moderate-release formulations
Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...
-
Sep 5, 2006Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population
Boston Scientific Corporation (NYSE: BSX) today announced six-month results from Phase I of its global TAXUS OLYMPIA registry,...
-
Sep 5, 2006International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent
Boston Scientific Corporation (NYSE: BSX) today welcomed the results of Abbott's SPIRIT II clinical trial, which reaffirmed...
-
Sep 1, 2006PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems
Boston Scientific Corporation (NYSE: BSX) today announced plans for the anticipated International launch of its PROMUS™(1) Everolimus-Eluting...
-
Aug 31, 2006Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system
Boston Scientific Corporation (NYSE: BSX) announced today that enrollment has exceeded 13,000 patients in the TAXUS OLYMPIA registry, designed to...
-
Aug 30, 2006
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the European...
-
Aug 23, 2006
ACME, Inc. has named Charlie Young senior vice president of marketing. Young comes to the company with more than 18 years of marketing experience. Young will oversee and direct the company's...
-
Jul 27, 2006
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the second quarter ended June 30, 2006. Highlights: - Acquisition...
-
Jul 26, 2006Precision™ SCS System, the first and smallest rechargeable system, achieves rapid adoption
Boston Scientific Corporation (NYSE: BSX) announced today that 5,000 patients with severe chronic pain have now been treated with the Precision™...
-
Jul 24, 2006Initial six-month results consistent with previous TAXUS registries
Boston Scientific Corporation (NYSE: BSX) today announced preliminary six-month results from Phase I of its global...